Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Haemophilia Stories

2012-09-13 02:28:18

CAMBRIDGE, Mass., Sept. 13, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., an emerging biopharmaceutical company developing new treatment options for people with hemophilia, today announced that John P. Butler, Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012. The presentation will take place at 4:00 p.m. ET at the Grand Hyatt Hotel in New York. About Inspiration BiopharmaceuticalsAs the only biopharmaceutical...

2012-09-10 22:23:11

LONDON and MOSCOW, September 11, 2012 /PRNewswire/ -- Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous...

2012-09-09 22:24:27

LONDON and MOSCOW, September 10, 2012 /PRNewswire/ -- Pro Bono Bio Group plc ("PBB"), the international healthcare group, and PolyTherics Limited ("PolyTherics"), a provider of solutions for the development of better biopharmaceuticals, announce further progress on their haematology alliance to produce longer-acting versions of blood factor proteins. Following an agreement between the parties in May 2012, PBB and PolyTherics undertook a feasibility programme to evaluate...

2012-08-21 02:27:57

In the news release, Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen, issued 21-Aug-2012 by Inspiration Biopharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first subheadline should read "Ipsen to pay Inspiration $30 million, with additional payments and investments totaling up to a potential value of $215 million" rather than "Ipsen to pay Inspiration $30 million, with additional payments and investments totaling up to...

2012-08-20 18:20:50

CAMBRIDGE, Mass., Aug. 21, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals Inc. (Inspiration) today announced new license, development and commercialization agreements with its strategic partner, Ipsen (Euronext: IPN, ADR: IPSEY). The agreements restructure the existing partnership with Ipsen and provide Inspiration with additional funding to support development of its two investigational drugs in late-stage development for hemophilia, IB1001 and OBI-1. Under the terms of these...

2012-08-02 02:31:58

CAMBRIDGE, Mass., Aug. 2, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that it has added new leaders who will play pivotal roles as the company moves toward commercialization of products in late-stage development for hemophilia. Inspiration has appointed Robert Corcoran as Senior Vice President, Quality, Mike Keavany as Vice President of Commercial Operations, North America, Mark De Rosch, Ph.D., as Vice President, Regulatory Affairs, Neil Schauer,...

2012-07-11 22:21:12

WAYNE, N.J., July 12, 2012 /PRNewswire/ -- Bayer HealthCare announced results from SPINART, a study designed to evaluate the effect of secondary prophylaxis with Kogenate® FS - antihemophilic factor (recombinant) on bleeding frequency and joint damage compared to on-demand treatment in adults and adolescents with severe hemophilia A. These data were presented as a late-breaker at the 50(th) annual World Federation of Hemophilia (WFH) World Congress, July 8-12, in Paris, France. In the...

2012-07-09 22:20:38

WAYNE, N.J., July 10, 2012 /PRNewswire/ -- Bayer HealthCare today announced the 2012 recipients of the Bayer Hemophilia Awards Program (BHAP). This year, the company awards a total of approximately $2.3 million USD in funding to 15 recipients in nine countries. BHAP is the largest program of its kind in hemophilia, funding innovative research and educational initiatives around the world. As such, BHAP is part of Bayer's commitment to research, support and disease management in hemophilia....

2012-07-09 18:20:50

CAMBRIDGE, Mass., July 10, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on clinical trials evaluating the safety and efficacy of IB1001, an intravenous recombinant factor IX (rFIX) being investigated for the treatment and prevention of bleeding episodes in people with hemophilia B. The clinical hold impacts two ongoing...

2012-07-08 22:21:10

PARIS, July 9, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds. Edward Gomperts, MD, Attending...